Side-by-side · Research reference
Melanotan-IIvsPancragen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1HUMAN-REVIEWED9/43 cited
BAnimal-StrongHUMAN-REVIEWED23/39 cited
Melanotan-II
MC1R + MC4R agonist · Tanning + sexual response
SQ · Abdomen · Loading 5–7 days, then maintenance
01Mechanism of Action
Parameter
Melanotan-II
Pancragen
Primary target
MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
Pathway
MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996Simerly 2023
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Downstream effect
Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Feedback intact?
—
Yes — preserves physiological glucose-insulin response
Origin
Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Antibody development
—
—
02Dosage Protocols
Parameter
Melanotan-II
Pancragen
Maintenance
0.5–1.0 mg 1–2×/week
After visible tan develops; supports with UV exposure.
—
Lower / starter dose
0.1 mg / day
Conservative starter — assess tolerability for nausea.
—
Evidence basis
Phase 1 + anecdotalDorr 1996
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
Duration
8–12 weeks per cycle
—
Reconstitution
Bacteriostatic water; protect from light
—
Timing
Evening preferred (24h tan-development cycle)
—
Half-life
~1 hour plasma; effects on melanocytes persist days
—
Primate dose (rhesus macaque)
—
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Diabetes model
—
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
04Side Effects & Safety
Parameter
Melanotan-II
Pancragen
Nausea
Common, especially loading phase
—
Flushing
Common transient
—
Increased mole / freckle pigmentation
Existing moles darken; new lesions possible
—
Melanoma risk
Theoretical concern — increased melanocyte activity; CAUTION in melanoma history
—
Appetite suppression
MC4R-mediated; mild
—
Pregnancy / OB
Contraindicated
—
Reported adverse events
—
None documented in primate studies
Human safety data
—
No published human trials; clinical use limited to Russian gerontology protocols
Absolute Contraindications
Melanotan-II
- ·History of melanoma or atypical mole syndrome
- ·Pregnancy / breastfeeding
- ·Active uncontrolled hypertension
Pancragen
—Relative Contraindications
Melanotan-II
- ·Significant freckling / dysplastic nevus
- ·Personal or family melanoma history
Pancragen
- ·Active pancreatic malignancy (proliferation marker upregulation)
05Administration Protocol
Parameter
Melanotan-II
Pancragen
1. Reconstitution
Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
2. Injection site
SQ — abdomen. Rotate sites.
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
3. Timing
Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.
No specific timing constraints documented. Administered once daily in primate protocols.
4. Storage
Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
5. Needle
29–31G insulin syringe.
—